



SomnoMed US Medical Advisory Board formed

24 July 2013, SomnoMed Limited (ASX:SOM) is pleased to announce the formation of its US Medical Advisory Board (MAB), a key element in the execution of its strategy to drive awareness, adoption and increase penetration of Continuous Open Airway Therapy (COAT) to sleep physicians and the medical market.

Collectively the members of the MAB have over fifty years of knowledge and experience in the treatment of sleep disorders. Importantly they have diverse backgrounds and practices with clinical training in pulmonary medicine, critical care, neurology, psychiatry, ENT and dentistry and clinical practice settings that encompass private practices, teaching institutions and managed care organizations. We believe this wealth and diversity of experience will greatly enhance the development of SomnoMed's medical device strategy.

The initial appointees to the Board are:

Dennis Hwang, MD. Dr. Hwang is the Director of Sleep Medicine for Kaiser Permanente in Fontana, CA. He is active in clinical research in the field of obstructive sleep apnea and holds a faculty appointment at New York University, Division of Pulmonary and Sleep Medicine;

Gandis Mazeika, MD. Dr. Mazeika is the founder of Sound Sleep Health Seattle, an innovative model in sleep practice. Dedicated to public education about sleep matters, he obtained his medical degree at the UC Davis School of Medicine and completed a joint residency in Psychiatry and Neurology through Harvard Medical School and Duke University Medical Center, followed by a Neurology and Sleep Disorders fellowship at Duke. He maintains Board Certification in Sleep Medicine and Psychiatry;

Edward Sall, MD, DDS, MBA. Dr Sall is a board certified in Otolaryngology, surgeon of the ear, nose, throat, head and neck. He is also a licensed dentist. His dual licensures corroborate his special interests of Sleep Apnea, Dental and Medical Sleep Medicine, TMJ dysfunction, Migraines and Craniofacial pain. He is currently the Department Chairman of Otolaryngology at Community General Hospital and a consultant to the Community General Hospital Sleep Center. He is board certified in Sleep Medicine; and

Jagdeep Bijwadia, MD. Dr Bijwadia was recently appointed Chief Medical Officer of SomnoMed. He is a sleep physician with HealthPartners in Minneapolis, MN. Board certified in internal medicine, pulmonary medicine and sleep, Dr. Bijwadia is active in clinical research and also holds a faculty position as assistant professor in the division of pulmonary, critical care, and sleep medicine at the University of Minnesota. Dr Bijwadia will also act as Chair of the MAB for its first term.

The Charter of the MAB is to provide SomnoMed with the most up to date knowledge and current thinking in the area of sleep medicine, including clinical practice protocols, treatment determination, key products and services, reimbursement and health economic considerations, and assist in the development of clinical data. The MAB will also provide input on medical education programs, and commercialization programs. They may also participate in clinical research projects and medical education initiatives.

The MAB will provide valuable insight in the development of future product/projects, such as DentiTrac®, the compliance micro-recorder that is scheduled for market introduction in August, and the MATRx sleep diagnostic test. DentiTrac® will allow definitive tracking of SomnoDent® usage for patients, clinicians, and payers. The new technologies of DentiTrac® and MATRx are key drivers for increased collaboration between sleep physicians and sleep dentists and the advice provided by the MAB in relation to these matters will be invaluable.

Contact: Dr. Peter Neustadt – Executive Chairman, SomnoMed Limited

Ph +61 2 9467 0400 or +61 (0) 414 566 592-m